IL13 and Nasal polyposis: For example, a human anti‐IL‐4Rα monoclonal antibody which interrupts signaling of both IL‐4 and IL‐13 has demonstrated convincing efficacy in controlling moderate‐to‐severe atopic dermatitis,25 allergic asthma,26 and nasal polyps.27